Subcutaneous Calcitonin in Acute Herpes Zoster

Recruiting Phase 3 Interventional Study
Calcitonin Subcutaneous Acute Herpes Zoster
Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
50 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Prevention
Participants needed
168 (estimated)
Sponsor
Tanta University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This prospective randomized controlled study will be conducted to evaluate the effect of adding calcitonin to the standard treatment protocol in patients with acute herpes zoster infection.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * patients aged ≥ 50 years, with acute herpes zoster infection (rash duration \< 7 days) and moderate to severe pain. Exclusion Criteria: * Coagulation abnormalities * Pre-existing other pain syndrome or psychological disorders. * Severe hepatic, cardiovascular, or renal disor…
Contacts

Amira M Elkeblawy, MD

01148529429

marmoramero999@gmail.com

CONTACT